DGAP-News: sterna biologicals GmbH & Co. KG / Key word(s): Miscellaneous sterna biologicals GmbH & Co. KG: STERNA BIOLOGICALS RECEIVES APPROVAL FOR INNOVATIVE PHASE II A STUDY DESIGN IN ASTHMA
DGAP-News: sterna biologicals GmbH & Co. KG / Key word(s): Miscellaneous sterna biologicals GmbH & Co. KG: STERNA BIOLOGICALS RECEIVES APPROVAL FOR INNOVATIVE PHASE II A STUDY DESIGN IN ASTHMA COMBINING A NOVEL ANTISENSE-BASED TREATMENT WITH A DIGITAL THERAPY 23.11.2021 / 14:00 The issue.
DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Personnel
Secarna Pharmaceuticals appoints Alexander Gebauer, MD, PhD as CEO and Managing Director
04.02.2021 / 14:00
Secarna Pharmaceuticals appoints Alexander Gebauer, MD, PhD as CEO and Managing Director
Munich/Martinsried, Germany, February 04, 2021 - Secarna Pharmaceuticals GmbH & Co. KG ( Secarna ), a biopharmaceutical company focusing on the discovery and development of next generation antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets via its LNAplus
TM platform, announced today that the Company has appointed Alexander Gebauer, MD, PhD as CEO and Managing Director. Dr. Gebauer brings more than 25 years of experience in the pharmaceutical and biotechnology industry in leadership roles in North America, Europe and India. His focus has been on R&D, from early discovery up to launch and life cycle management, as well as business development and designing and impl
Press release content from Accesswire. The AP news staff was not involved in its creation.
sterna biologicals GmbH & Co. KG Raises Further EUR 10.0 Million (approx. USD 11.9 million) in Series A - 2nd Closing Private Placement
January 7, 2021 GMT
Following successful completion of the company’s Series A - 1st closing with EUR 12.0 million in April 2020, sterna now has successfully completed a 2nd closing with another EUR 10.0 million, bringing the Series A total to EUR 22.0 million
Proceeds from the 2nd closing will fund phase IIb preparatory activities including toxicology studies and CMC work for SB010 in moderate to severe asthma as well as the completion of an oral formulation project for SB012 laying the foundation for phase I/IIb studies in moderate to severe ulcerative colitis
DGAP-News: stern .
DGAP-News: sterna biologicals GmbH & Co. KG raises further EUR 10.0 million (approx. USD 11.9 million) in Series A - 2nd closing private placement
vom 07.01.2021, 15:00 Uhr
Bild: pixabay.com
DGAP-News: sterna biologicals GmbH & Co. KG / Key word(s): Financing
sterna biologicals GmbH & Co. KG raises further EUR 10.0 million (approx. USD 11.9 million) in Series A - 2nd closing private placement
07.01.2021 / 15:00
STERNA BIOLOGICALS RAISES FURTHER EUR 10.0 MILLION (APPROX. USD 11.9 MILLION) IN SERIES A - 2
nd CLOSING PRIVATE PLACEMENT
Following successful completion of the company s Series A - 1
st closing with EUR 12.0 million in April 2020, sterna now has successfully completed a 2
nd closing with another EUR 10.0 million, bringing the Series A total to EUR 22.0 million